Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
13.72
+0.10 (0.73%)
At close: May 7, 2026, 4:00 PM EDT
13.85
+0.13 (0.95%)
After-hours: May 7, 2026, 6:54 PM EDT
← View all transcripts

AGM 2026

May 6, 2026

Operator

Welcome to the annual meeting for Amneal Pharmaceuticals, Inc. Our host for today's call is Paul Meister, Chairman. I will now turn the call over to your host. Mr. Meister, you may begin.

Paul Meister
Chairman, Amneal Pharmaceuticals, Inc

Thank you. Good morning, ladies and gentlemen. It is 9:00 A.M., and I would like to officially call to order the 2026 annual meeting of stockholders of Amneal Pharmaceuticals, Inc. I'm Paul Meister, the Chairman of the Board, and I will be presiding over this meeting today. We are conducting the annual meeting virtually again this year. The agenda and rules of conduct have been provided on the virtual meeting website and outline how we will proceed with today's meeting. To conduct an informative, orderly, and constructive meeting, we ask that participants abide by these rules. As stated in the rules of conduct, if you would like to submit a question, you may do so following the instructions on the meeting website. We ask that you limit yourself to one question or comment and restrict your questions to matters of general interest to our stockholders.

Thank you for your cooperation with these rules. Chirag Patel, the company's Co-Founder, Co-Chief Executive Officer, President, and Director is joining us today, as is Jason Daly, the company's Chief Legal Officer, Executive Vice President, and Corporate Secretary. Jason will act as secretary for the meeting. Also joining today's meetings are our Inspector of Election, John Merva of American Election Services, and Anthony Sgammato of Ernst & Young, the company's independent auditor. The first order of business before us is a report from the secretary. Mr. Secretary, will you please advise us whether the meeting is duly constituted?

Jason Daly
EVP, Chief Legal Officer, and Corporate Secretary, Amneal Pharmaceuticals, Inc

Mr. Chairman, I have an affidavit of distribution from Broadridge Financial Solutions stating that the notice of this meeting and proxy materials were mailed beginning March 25, 2026 to all stockholders of record as of the close of business on March 12, 2026. We are informed that more than 92% of the shares of Amneal's outstanding common stock entitled to vote at this meeting are present or represented by proxy. Therefore, we have a quorum present for the conduct of business, and this meeting is duly constituted.

Paul Meister
Chairman, Amneal Pharmaceuticals, Inc

Thank you, Mr. Secretary. The meeting is now open for the purpose of transacting business properly before it. The polls opened at the beginning of the meeting. We will close the polls on all matters immediately after the presentation of today's proposals. Most of you have already voted by proxy. Your shares will be voted accordingly. You do not need to vote again at this time unless you wish to change your vote. If anyone would like to vote now or revoke his or her prior vote, please follow the instructions on the meeting website before the polls close. I'll now present the proposals that our stockholders will be voting on at the meeting. All such proposals are further described in the proxy materials.

The first item of business is the election of the 10 individuals listed on our proxy statement to serve as directors until the 2027 annual meeting. The second item of business is an advisory, non-binding vote to approve the compensation of our named executive officers. The third item of business is the ratification of the appointment of Ernst & Young as our independent registered public accounting firm for 2026. The Board of Directors recommends a vote in favor of each director nominee and in favor of each of the other proposals. We'll now pause to address any stockholder questions we have received relating to these proposals.

Jason Daly
EVP, Chief Legal Officer, and Corporate Secretary, Amneal Pharmaceuticals, Inc

There are no questions relating to the proposals.

Paul Meister
Chairman, Amneal Pharmaceuticals, Inc

Seeing no questions on the proposals, I now declare the polls closed. The Inspector of Election is ready. I ask the Secretary to report on the preliminary voting results.

Jason Daly
EVP, Chief Legal Officer, and Corporate Secretary, Amneal Pharmaceuticals, Inc

Mr. Chairman, we have been informed by the Inspector of Election that based on the preliminary voting results, each nominee for election to the Board of Directors has been duly elected and each of the other proposals voted on has been approved. Following the meeting, we will publicly announce the official voting results once all the verifications have been completed by the Inspector of Election.

Paul Meister
Chairman, Amneal Pharmaceuticals, Inc

Thank you, Mr. Secretary. The legal portion of the meeting is now adjourned. We will not provide a formal business update at today's meeting, but instead invite all of our stockholders to listen to the replay of our earnings call for the first quarter of 2026, which was held on April 22nd and posted in the investors section of our website. We will now address general stockholder questions we have received in accordance with the meeting rules of conduct.

Jason Daly
EVP, Chief Legal Officer, and Corporate Secretary, Amneal Pharmaceuticals, Inc

Mr. Chairman, we have no questions to answer.

Paul Meister
Chairman, Amneal Pharmaceuticals, Inc

There being no questions, this concludes our 2026 annual meeting with stockholders. Thank you for participating.

Operator

This now concludes the meeting. Thank you for attending, and have a wonderful rest of your day.

Jason Daly
EVP, Chief Legal Officer, and Corporate Secretary, Amneal Pharmaceuticals, Inc

Thank you.

Powered by